Ethereal Echoes: Sketches And Recent Works, an evocative solo exhibition that traces the four-decade artistic journey of ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Savara (SVRA – Research Report) and Intellia Therapeutics (NTLA – Research Rep ...

SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral ...

Rani Therapeutics announced positive preclinical data for RT-114 and semaglutide, advancing toward Phase 1 obesity trials in mid-2025. Rani Therapeutics Holdings, Inc. has announced preclinical ...

Detailed price information for Rani Therapeutics Holdings Inc Cl A (RANI-Q) from The Globe and Mail including charting and trades.

SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or“Rani”) (Nasdaq: RANI), a clinical-stage ...

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a pharmaceutical company trading at $1.09 per share, disclosed on Monday that it has received a notice from the Nasdaq Stock Exchange regarding ...

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a pharmaceutical company trading at $1.09 per share, disclosed on Monday that it has received a notice from the Nasdaq Stock Exchange regarding non ...

March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

Please go ahead. Thank you, Operator. Please turn to Slide 2. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford.

March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...